Description
Dacarbazine is not commonly used in the treatment of colorectal cancer (CRC). It has been primarily investigated for other types of cancers such as melanoma. Its use in CRC remains investigational and it is not recommended as standard therapy in any line of treatment for CRC based on current clinical evidence.
Mechanism of Action
Dacarbazine is an alkylating agent that interferes with DNA replication and repair, leading to cell death.
Side Effects
Myelosuppression; nausea and vomiting; alopecia; anorexia; fatigue; constipation
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT00600496
Phase 1
Active, not recruiting
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
United States